Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Lupin to lays off...

    Lupin to lays off employees from RnD Divsion

    Farhat NasimWritten by Farhat Nasim Published On 2019-03-15T18:01:15+05:30  |  Updated On 16 Aug 2021 4:23 PM IST

    Mumbai: Facing a Setback in its business turf, one the largest manufacturers of medicines in the country Lupin Ltd is taking steps to rationalize its research operations, and was recently seen laying off as many of its employees at Pune. The firm will witness a business transition from making plain generic drugs to more complicated and speciality products, a move which will lead to exit of more than 60 employees according to certain media reports. The exact numbers of employees which would be terminated is currently not disclosed.


    According to recent media reports, pricing pressure and a challenging US market have prompted the pharma giant to discontinue employment of more than 60 employees from Research and Development(R&D), chiefly derma formulation, analytics and active pharmaceutical ingredients (API) research.


    Industry experts are of the opinion that companies restructure pipelines, cut down R&D budgets and terminate staff to tide over tough times.


    Also Read: Lupin launches Minocycline Hydrochloride extended release tablets in US


    Lupin has 1700 scientists across nine research and development centres in different countries including two in India, at Pune and Aurangabad.


    Confirmation to the same was given as a Lupin spokesperson told BusinessLine, "The US generic market has gone through significant changes in the last few years and we wanted to optimise our research structure in line with our future pipeline. These (job) cuts were necessary in line with the changes in the market place. In that, we have also re-deployed a good number of scientists in functions which we are expanding. We took a long term view on the research pipeline in doing this exercise and we do no anticipate further cuts."


    However, the company's representative did not put a number to the employees who were impacted by this exercise, and also, did not confirm industry information doing the rounds that fixed the number of employees being terminated at 60, across segments including dermatology and APIs.


    As per the daily, the streamlining exercise currently being carried out at Lupin was possibly the last leg. A similar rationalization had been undertaken in 2018 as well, where the company had let go of about 50 people.


    The domestic pharmaceutical sector has been undergoing stiff headwinds over the last few months, with margins of most drug companies under pressure, bogged down by price erosion in US businesses and regulatory issues affecting major companies. To double the trouble, their domestic businesses are also impacted by the implementation of Goods and Services Act.


    "Research is a key driver of our growth and we are committed to investing in our focus areas of generics, complex generics (including areas of inhalation and complex injectables), APIs (Active Pharmaceutical Ingredients), biosimilars, speciality and drug discovery", said Lupin.


    Speaking to TOI, a company official told that majority of employees who were asked to leave were serving junior functions. Lupin is not shutting down its R&D unit, he stated, adding, "We are rationalising the early-stage drug discovery programme to focus on other near-term and mid-term opportunities for Lupin — complex generics and speciality. This does not have any impact on our late-stage developments — from our novel drug delivery system (NDDS) pipeline — which continue as such."


    According to the daily, the company will continue to focus on the late-stage developments from their NCE pipeline. "We currently have three compounds in Phase II clinical trials. We will continue to focus on select high-value early-stage NCE (new chemical entity) opportunities also", he added.


    Also Read: Lupin gets USFDA nod for Atorvastatin Calcium tablets to lower cholesterol

    APIsbiosimilarsbusiness newscomplex genericscomplex injectablesdrugemployeesGSTinhalationLupinlupin latestlupin newslupin terminateNCENDDSspecialityspeciality generics
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok